- Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
Briana M. Choi et al, 2021, Journal of Medical Economics CrossRef - Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
Vanessa Arciero et al, 2022, JNCI Cancer Spectrum CrossRef - Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials
Aditi A Kharat et al, 2021, Journal of Managed Care & Specialty Pharmacy CrossRef - French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients
Amaury Demaziere et al, 2024, Therapeutic Advances in Medical Oncology CrossRef - Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreatic Ductal Adenocarcinoma
Yoshihiko Fukukura et al, 2019, Pancreas CrossRef - Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma
Satoshi Okubo et al, 2019, Scientific Reports CrossRef - Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma
Nan Lee et al, 2021, Cancer Biomarkers CrossRef - A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study
Taiga Otsuka et al, 2021, International Journal of Clinical Oncology CrossRef - Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
Keisuke Okuno et al, 2022, Pharmaceuticals CrossRef - Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
Keisuke Okuno et al, 2023, Biomedicines CrossRef - Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma
Yoshihiko Fukukura et al, 2020, Pancreatology CrossRef - Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan
Kosuke Morimoto et al, 2022, Value in Health Regional Issues CrossRef